GWA
ACAD icon

Genesis Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Genesis Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$37.7K Hold
900
– – 0.03% 211
2015
Q1 		$28.8K Hold
900
– – 0.02% 252
2014
Q4 		$33.7K Buy
+900
New +$25.5K 0.03% 259

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Genesis Wealth Advisors's ACAD Position: Q2 2015 in Review

Genesis Wealth Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2015 at 900 shares worth $37.7K. The position accounts for 0.03% of the portfolio, ranked #211.

Genesis Wealth Advisors first reported a position in ACAD in Q4 2014 and has held it in 3 quarters since. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • Genesis Wealth Advisors held 900 shares of Acadia Pharmaceuticals worth $37.7K as of Q2 2015.
  • Genesis Wealth Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2015.
  • Acadia Pharmaceuticals made up 0.03% of Genesis Wealth Advisors's portfolio in Q2 2015, its #211 holding.
  • Genesis Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 3 quarters since.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on Genesis Wealth Advisors's 13F filing for Q2 2015, filed 24 Aug 2015.